# Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)

> **NCT05675111** · — · COMPLETED · sponsor: **Nanjing Medical University** · enrollment: 12408 (actual)

## Conditions studied

- Immune Checkpoint Inhibitor
- Endocrine Toxicity

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05675111
- **Lead sponsor:** Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-10-30
- **Target enrollment:** 12408 (ACTUAL)
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05675111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05675111, "Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05675111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*